missing translation for 'onlineSavingsMsg'
Learn More
Learn More
ICAM1 Monoclonal Antibody (OTI2H4), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA506870
This item is not returnable.
View return policy
Description
ICAM-1 (CD54) is an 85-110 kDa single-chain type 1 integral membrane glycoprotein with an extracellular domain of five immunoglobulin superfamily repeats, a transmembrane region and a cytoplasmic domain. ICAM-1 has 7 potential N-linked glycosylation sites and shares considerable amino acid sequence homology with ICAM-3 (CD50) and ICAM-2 (CD102). ICAM-1 binds to integrins of type CD11a/CD18 (leukocyte adhesion molecule, LFA-1), or CD11b/CD18 (Mac-1) and is exploited by Rhinovirus as a receptor. ICAM-1 is expressed by activated endothelial cells and detected on epithelial cells, fibroblasts, chondrocytes, B lymphocytes, T lymphocytes (low), monocytes, macrophages, dendritic cells and neutrophils, with lower levels that increase upon inflammation. ICAM-1 is also detected in some carcinoma and melanoma cells. Soluble ICAM-1 is detectable in the plasma and is elevated in patients with various inflammatory syndromes.Specifications
| ICAM1 | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| P05362 | |
| ICAM1 | |
| Full length human recombit protein of human ICAM1 produced in HEK293T cell. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 |
| Immunohistochemistry (Paraffin), Western Blot | |
| OTI2H4 | |
| Unconjugated | |
| ICAM1 | |
| BB2, CD54, P3.58 | |
| Mouse | |
| Affinity Chromatography | |
| RUO | |
| 3383 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction